Allogene Therapeutics

Allogene Therapeutics Overview

Founded 2017
Founded
Status Public
Employees 206
Employees
Stock Symbol ALLO
Stock Symbol
Investments 1
Share Price $54.04 (As of Friday Closing)

Allogene Therapeutics General Information

Description

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Primary Office
  • 210 East Grand Avenue
  • South San Francisco, CA 94080
  • United States
+1 (415) 000-0000

Allogene Therapeutics Timeline

201820192020
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Allogene Therapeutics Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$54.04 $50.20 $17.43 - $54.34 $6.77B 125M 1.03M -$1.99

Allogene Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
Enterprise Value 1,949,007 2,703,462 3,603,635
Revenue 0 0 0
EBITDA (217,180) (197,249) (212,553)
Net Income (207,488) (184,594) (211,505)
Total Assets 688,523 717,802 773,855
Total Debt 51,536 51,349 34,456
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Allogene Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Allogene Therapeutics‘s full profile, request access.

Request a free trial

Allogene Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Allogene Therapeutics‘s full profile, request access.

Request a free trial

Allogene Therapeutics Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
TCR2 Therapeutics Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000000000 Formerly VC-backed Culver City, CA 000 00000 00000000000 00000
000000 00000000000 Venture Capital-Backed Emeryville, CA 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Watertown, MA 00 00000 000000000 00000

Allogene Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
David Chang Ph.D Chief Executive Officer & Founder
Eric Schmidt Ph.D Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Alison Moore Ph.D Chief Technology Officer, Technology
Barbra Sasu Ph.D Chief Scientific Officer
Christine Cassiano Chief Communications Officer

Allogene Therapeutics Board Members (9)

To view Allogene Therapeutics‘s full board member team, request access >>
Name Representing Role Since
Arie Belldegrun MD Self Chairman & Founder 000 0000
David Bonderman JD Self Board Member 000 0000
Deborah Messemer Allogene Therapeutics Board Member 000 0000
Franz Humer Ph.D Allogene Therapeutics Board Member 000 0000
John DeYoung Self Board Member 000 0000

1 Former Board Member

Allogene Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Allogene Therapeutics‘s full profile, request access.

Request a free trial

Allogene Therapeutics Investments (1)

To view Allogene Therapeutics‘s complete investment and acquisition history, request access >>
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 01-Nov-2019 0000 00000 00.000 Drug Discovery 00000 00000 00.0